{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:08:58Z","timestamp":1791842938861,"version":"4.3.4"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmic Physiol. Opt."],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s44402-026-00071-x","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:54:07Z","timestamp":1776059647000},"page":"635-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control\u2014A Narrative Review"],"prefix":"10.1007","volume":"46","author":[{"given":"Swapnil","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Bullimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan K.","family":"Verkicharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"71_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/aos.13790","volume":"96","author":"C Lind\u00e9n","year":"2018","unstructured":"Lind\u00e9n C, Heijl A, J\u00f3hannesson G, Aspberg J, Andersson Geimer S, Bengtsson B. Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study. Acta Ophthalmol. 2018;96:567\u201372. https:\/\/doi.org\/10.1111\/aos.13790.","journal-title":"Acta Ophthalmol"},{"key":"71_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.62.5.3","volume":"62","author":"IG Morgan","year":"2021","unstructured":"Morgan IG, Wu PC, Ostrin LA, Tideman JWL, Yam JC, Lan W, et al. IMI risk factors for myopia. Invest Ophthalmol Vis Sci. 2021;62:3. https:\/\/doi.org\/10.1167\/iovs.62.5.3.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith Iii EL, Zhou X, et al. Myopia. Nat Rev Dis Prim. 2020;6:99. https:\/\/doi.org\/10.1038\/s41572-020-00231-4.","journal-title":"Nat Rev Dis Prim"},{"key":"71_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101156","volume":"96","author":"JB Jonas","year":"2023","unstructured":"Jonas JB, Jonas RA, Bikbov MM, Wang YX, Panda-Jonas S. Myopia: Histology, clinical features and potential implications for the etiology of axial elongation. Prog Retin Eye Res. 2023;96:101156. https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101156.","journal-title":"Prog Retin Eye Res"},{"key":"71_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","volume":"62","author":"K Ohno-Matsui","year":"2021","unstructured":"Ohno-Matsui K, Wu PC, Yamashiro K, Vutipongsatorn K, Fang Y, Cheung CMG, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021;62:5. https:\/\/doi.org\/10.1167\/iovs.62.5.5.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/opx.0000000000000505","volume":"92","author":"JK Si","year":"2015","unstructured":"Si JK, Tang K, Bi HS, Guo DD, Guo JG, Wang XR. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci. 2015;92:252\u20137. https:\/\/doi.org\/10.1097\/opx.0000000000000505.","journal-title":"Optom Vis Sci"},{"key":"71_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/icl.0000000000001006","volume":"49","author":"K Tang","year":"2023","unstructured":"Tang K, Si J, Wang X, Lu X, Bi H. Orthokeratology for slowing myopia progression in children: a systematic review and meta-analysis of randomized controlled trials. Eye Contact Lens. 2023;49:404\u201310. https:\/\/doi.org\/10.1097\/icl.0000000000001006.","journal-title":"Eye Contact Lens"},{"key":"71_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32700-7","volume":"13","author":"CSY Lam","year":"2023","unstructured":"Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13:5475. https:\/\/doi.org\/10.1038\/s41598-023-32700-7.","journal-title":"Sci Rep"},{"key":"71_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40662-025-00427-3","volume":"12","author":"X Li","year":"2025","unstructured":"Li X, Huang Y, Liu C, Chang X, Cui Z, Yang Q, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis (Lond). 2025;12:10. https:\/\/doi.org\/10.1186\/s40662-025-00427-3.","journal-title":"Eye Vis (Lond)"},{"key":"71_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/opx.0000000000001410","volume":"96","author":"P Chamberlain","year":"2019","unstructured":"Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96:556\u201367. https:\/\/doi.org\/10.1097\/opx.0000000000001410.","journal-title":"Optom Vis Sci"},{"key":"71_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/opx.0000000000001873","volume":"99","author":"P Chamberlain","year":"2022","unstructured":"Chamberlain P, Bradley A, Arumugam B, Hammond D, McNally J, Logan NS, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. Optom Vis Sci. 2022;99:204\u201312. https:\/\/doi.org\/10.1097\/opx.0000000000001873.","journal-title":"Optom Vis Sci"},{"key":"71_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"324","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Walker MK, Mutti DO, Jones-Jordan LA, Sinnott LT, Giannoni AG, et al. Effect of high add power, medium add power or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA. 2020;324:571\u201380. https:\/\/doi.org\/10.1001\/jama.2020.10834.","journal-title":"JAMA"},{"key":"71_CR13","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1136\/bjo-2023-323651","volume":"108","author":"MK Manoharan","year":"2024","unstructured":"Manoharan MK, Verkicharla PK. Randomised clinical trial of extended depth of focus lenses for controlling myopia progression: outcomes from SEED LVPEI Indian Myopia Study. Br J Ophthalmol. 2024;108:1292\u20138. https:\/\/doi.org\/10.1136\/bjo-2023-323651.","journal-title":"Br J Ophthalmol"},{"key":"71_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40123-022-00536-5","volume":"11","author":"EP Shen","year":"2022","unstructured":"Shen EP, Chu HS, Cheng HC, Tsai TH. Center-for-near extended-depth-of-focus soft contact lens for myopia control in children: 1-year results of a randomized controlled trial. Ophthalmol Ther. 2022;11:1577\u201388. https:\/\/doi.org\/10.1007\/s40123-022-00536-5.","journal-title":"Ophthalmol Ther"},{"key":"71_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/opo.12621","volume":"39","author":"P Sankaridurg","year":"2019","unstructured":"Sankaridurg P, Bakaraju RC, Naduvilath T, Chen X, Weng R, Tilia D, et al. Myopia control with novel central and peripheral plus contact lenses and extended depth of focus contact lenses: 2 year results from a randomised clinical trial. Ophthalmic Physiol Opt. 2019;39:294\u2013307. https:\/\/doi.org\/10.1111\/opo.12621.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2023.11.025","volume":"260","author":"S D\u00edaz-G\u00f3mez","year":"2024","unstructured":"D\u00edaz-G\u00f3mez S, Burgos-Mart\u00ednez M, Sankaridurg P, Urkia-Solorzano A, Carballo-\u00c1lvarez J. Two-year myopia management efficacy of extended depth of focus soft contact lenses (MYLO) in Caucasian children. Am J Ophthalmol. 2024;260:122\u201331. https:\/\/doi.org\/10.1016\/j.ajo.2023.11.025.","journal-title":"Am J Ophthalmol"},{"key":"71_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025% and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"key":"71_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis. Ophthalmology. 2022;129:322\u201333. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.016.","journal-title":"Ophthalmology"},{"key":"71_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ajo.2023.03.036","volume":"252","author":"J Tang","year":"2023","unstructured":"Tang J, Liao Y, Yan N, Dereje SB, Wang J, Luo Y, et al. Efficacy of repeated low-level red-light therapy for slowing the progression of childhood myopia: a systematic review and meta-analysis. Am J Ophthalmol. 2023;252:153\u201363. https:\/\/doi.org\/10.1016\/j.ajo.2023.03.036.","journal-title":"Am J Ophthalmol"},{"key":"71_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2021","unstructured":"Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100923.","journal-title":"Prog Retin Eye Res"},{"key":"71_CR21","doi-asserted-by":"publisher","first-page":"Cd014758","DOI":"10.1002\/14651858.CD014758.pub3","volume":"2","author":"JG Lawrenson","year":"2025","unstructured":"Lawrenson JG, Huntjens B, Virgili G, Ng S, Dhakal R, Downie LE, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2025;2:Cd014758. https:\/\/doi.org\/10.1002\/14651858.CD014758.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"71_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.66.12.39","volume":"66","author":"MA Bullimore","year":"2025","unstructured":"Bullimore MA, Saunders KJ, Baraas RC, Berntsen DA, Chen Z, Chia AWL, et al. IMI-interventions for controlling myopia onset and progression 2025. Invest Ophthalmol Vis Sci. 2025;66:39. https:\/\/doi.org\/10.1167\/iovs.66.12.39.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.64.6.6","volume":"64","author":"JS Wolffsohn","year":"2023","unstructured":"Wolffsohn JS, Whayeb Y, Logan NS, Weng R. IMI-global trends in myopia management attitudes and strategies in clinical practice-2022 update. Invest Ophthalmol Vis Sci. 2023;64:6. https:\/\/doi.org\/10.1167\/iovs.64.6.6.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91089-7","volume":"15","author":"CY Lee","year":"2025","unstructured":"Lee CY, Yang SF, Chang YL, Huang JY, Lian IB, Chang CK. The effect of defocus incorporated multiple segment spectacles\u2019 lenses combined with different concentrations atropine for myopia control. Sci Rep. 2025;15:12356. https:\/\/doi.org\/10.1038\/s41598-025-91089-7.","journal-title":"Sci Rep"},{"key":"71_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102317","volume":"48","author":"X Cao","year":"2025","unstructured":"Cao X, Guo Z, Wei Z, Ming H, Ma B, Zhao Y, et al. Effect of 0.01% atropine eye drops combined with different optical treatments to control low myopia in Chinese children. Cont Lens Anterior Eye. 2025;48:102317. https:\/\/doi.org\/10.1016\/j.clae.2024.102317.","journal-title":"Cont Lens Anterior Eye"},{"key":"71_CR26","doi-asserted-by":"publisher","unstructured":"Xiao L, Lv J, Zhu X, Sun X, Dong W, Fang C. Therapeutic effects of orthokeratology lens combined with 0.01% atropine eye drops on juvenile myopia. Arq Bras Oftalmol. 2023.87. https:\/\/doi.org\/10.5935\/0004-2749.2022-0247.","DOI":"10.5935\/0004-2749.2022-0247"},{"key":"71_CR27","doi-asserted-by":"publisher","first-page":"12077","DOI":"10.2147\/jir.S539831","volume":"18","author":"H Wang","year":"2025","unstructured":"Wang H, Piao J, Yoo G, Li D, Liu J, In-Chul J. Investigation into the therapeutic efficacy and inflammatory modulatory effects of the combined use of 0.01% atropine eye drops and orthokeratology lenses in the management of myopia among adolescent patients. J Inflamm Res. 2025;18:12077\u201387. https:\/\/doi.org\/10.2147\/jir.S539831.","journal-title":"J Inflamm Res"},{"key":"71_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04523-9","volume":"25","author":"M Chen","year":"2025","unstructured":"Chen M, Lei H, Yang X, Deng Z, Qu J, Mao X. Comparative efficacy of optical correction methods combined with 0.01% atropine in myopia control. BMC Ophthalmol. 2025;25:703. https:\/\/doi.org\/10.1186\/s12886-025-04523-9.","journal-title":"BMC Ophthalmol"},{"key":"71_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25599-z","volume":"12","author":"Z Huang","year":"2022","unstructured":"Huang Z, Chen XF, He T, Tang Y, Du CX. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12:22311. https:\/\/doi.org\/10.1038\/s41598-022-25599-z.","journal-title":"Sci Rep"},{"key":"71_CR30","doi-asserted-by":"publisher","first-page":"e0281816","DOI":"10.1371\/journal.pone.0281816","volume":"18","author":"P Nucci","year":"2023","unstructured":"Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine and combined DIMS\/atropine. PLoS ONE. 2023;18:e0281816. https:\/\/doi.org\/10.1371\/journal.pone.0281816.","journal-title":"PLoS ONE"},{"key":"71_CR31","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41433-024-02987-5","volume":"38","author":"T Tang","year":"2024","unstructured":"Tang T, Lu Y, Li X, Zhao H, Wang K, Li Y, et al. Comparison of the long-term effects of atropine in combination with orthokeratology and defocus incorporated multiple segment lenses for myopia control in Chinese children and adolescents. Eye. 2024;38:1660\u20137. https:\/\/doi.org\/10.1038\/s41433-024-02987-5.","journal-title":"Eye"},{"key":"71_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/bjo-2024-326852","volume":"109","author":"N Guemes-Villahoz","year":"2025","unstructured":"Guemes-Villahoz N, Talavero Gonz\u00e1lez P, Porras-\u00c1ngel P, Bella-Gala R, Ruiz-Pomeda A, Martin-Garcia B, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Br J Ophthalmol. 2025;109:1074\u201380. https:\/\/doi.org\/10.1136\/bjo-2024-326852.","journal-title":"Br J Ophthalmol"},{"key":"71_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100753","volume":"5","author":"BX Sim","year":"2025","unstructured":"Sim BX, Loh KL, Htoon HM, Sri Y, Balakrishnan M, Lin PCP, et al. Additive effect of highly aspherical lenslet target spectacles to children inadequately controlled by atropine monotherapy. Ophthalmol Sci. 2025;5:100753. https:\/\/doi.org\/10.1016\/j.xops.2025.100753.","journal-title":"Ophthalmol Sci"},{"key":"71_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102282","volume":"48","author":"L Wen","year":"2025","unstructured":"Wen L, Liu H, Xu Q, Pan W, Lin Z, Xiao Z, et al. Add-on effect of using 0.05% atropine in fast progressors of orthokeratology: a preliminary retrospective study. Cont Lens Anterior Eye. 2025;48:102282. https:\/\/doi.org\/10.1016\/j.clae.2024.102282.","journal-title":"Cont Lens Anterior Eye"},{"key":"71_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1358046","volume":"11","author":"B Li","year":"2024","unstructured":"Li B, Yu S, Gao S, Sun G, Pang X, Li X, et al. Effect of 0.01% atropine combined with orthokeratology lens on axial elongation: a 2-year randomized, double-masked, placebo-controlled, cross-over trial. Front Med. 2024;11:1358046. https:\/\/doi.org\/10.3389\/fmed.2024.1358046.","journal-title":"Front Med"},{"key":"71_CR36","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/bjo-2022-321272","volume":"107","author":"S Xu","year":"2023","unstructured":"Xu S, Li Z, Zhao W, Zheng B, Jiang J, Ye G, et al. Effect of atropine orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial. Br J Ophthalmol. 2023;107:1812\u20137. https:\/\/doi.org\/10.1136\/bjo-2022-321272.","journal-title":"Br J Ophthalmol"},{"key":"71_CR37","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s40123-023-00755-4","volume":"12","author":"L Du","year":"2023","unstructured":"Du L, Chen J, Ding L, Wang J, Yang J, Xie H, et al. Add-on effect of 0.01% atropine in orthokeratology wearers for myopia control in children: a 2-year retrospective study. Ophthalmol Ther. 2023;12:2557\u201368. https:\/\/doi.org\/10.1007\/s40123-023-00755-4.","journal-title":"Ophthalmol Ther"},{"key":"71_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2022.101723","volume":"46","author":"Q Tan","year":"2023","unstructured":"Tan Q, Ng AL, Cheng GP, Woo VC, Cho P. Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: a 2-year randomized clinical trial. Cont Lens Anterior Eye. 2023;46:101723. https:\/\/doi.org\/10.1016\/j.clae.2022.101723.","journal-title":"Cont Lens Anterior Eye"},{"key":"71_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02635-0","volume":"22","author":"S Yu","year":"2022","unstructured":"Yu S, Du L, Ji N, Li B, Pang X, Li X, et al. Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial. BMC Ophthalmol. 2022;22:438. https:\/\/doi.org\/10.1186\/s12886-022-02635-0.","journal-title":"BMC Ophthalmol"},{"key":"71_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/bjophthalmol-2020-317980","volume":"106","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhou J, Xue F, Qu X, Zhou X. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol. 2022;106:1069\u201372. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317980.","journal-title":"Br J Ophthalmol"},{"key":"71_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/opx.0000000000001884","volume":"99","author":"JH Jones","year":"2022","unstructured":"Jones JH, Mutti DO, Jones-Jordan LA, Walline JJ. Effect of combining 0.01% atropine with soft multifocal contact lenses on myopia progression in children. Optom Vis Sci. 2022;99:434\u201342. https:\/\/doi.org\/10.1097\/opx.0000000000001884.","journal-title":"Optom Vis Sci"},{"key":"71_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","volume":"40","author":"Q Tan","year":"2020","unstructured":"Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557\u201366. https:\/\/doi.org\/10.1111\/opo.12722.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:12750. https:\/\/doi.org\/10.1038\/s41598-020-69710-8.","journal-title":"Sci Rep"},{"key":"71_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clae.2018.10.026","volume":"42","author":"Z Chen","year":"2019","unstructured":"Chen Z, Huang S, Zhou J, Xiaomei Q, Zhou X, Xue F. Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children-a preliminary retrospective study. Cont Lens Anterior Eye. 2019;42:439\u201342. https:\/\/doi.org\/10.1016\/j.clae.2018.10.026.","journal-title":"Cont Lens Anterior Eye"},{"key":"71_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-018-0608-3","volume":"62","author":"N Kinoshita","year":"2018","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544\u201353. https:\/\/doi.org\/10.1007\/s10384-018-0608-3.","journal-title":"Jpn J Ophthalmol"},{"key":"71_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04584-w","volume":"25","author":"Y Tang","year":"2025","unstructured":"Tang Y, Song J, Huang Y, Mao X. Comparison of the effects of spectacle lenses with highly aspherical lenslets combined with atropine for moderate to high myopia control in children. BMC Ophthalmol. 2025;25:700. https:\/\/doi.org\/10.1186\/s12886-025-04584-w.","journal-title":"BMC Ophthalmol"},{"key":"71_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-22722-8","volume":"15","author":"Z Guo","year":"2025","unstructured":"Guo Z, Wei Z, Ming H, Zhang L, Ma B, Zhao Y, et al. Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children. Sci Rep. 2025;15:38911. https:\/\/doi.org\/10.1038\/s41598-025-22722-8.","journal-title":"Sci Rep"},{"key":"71_CR48","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s40123-025-01214-y","volume":"14","author":"M Gao","year":"2025","unstructured":"Gao M, Hou Y, Lu Y, Shi Z, Zhao Q. Efficacy and safety of 0.01% atropine eye drops and novel Lenslet-ARray-Integrated spectacle lenses for the prevention of myopia progression among children with premyopia: a randomized clinical trial. Ophthalmol Ther. 2025;14:2481\u201396. https:\/\/doi.org\/10.1007\/s40123-025-01214-y.","journal-title":"Ophthalmol Ther"},{"key":"71_CR49","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4103\/ijo.Ijo_3107_24","volume":"73","author":"S Xiong","year":"2025","unstructured":"Xiong S, Li X, Lu Y, Zhang M, Li Y, Wang K. Morning administration is more effective than evening administration of 0.01% atropine eye drops combined with orthokeratology for myopia control. Indian J Ophthalmol. 2025;73:1153\u20138. https:\/\/doi.org\/10.4103\/ijo.Ijo_3107_24.","journal-title":"Indian J Ophthalmol"},{"key":"71_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04151-3","volume":"25","author":"F Li","year":"2025","unstructured":"Li F, Mai X, Li Q, Mai X. Longitudinal safety and efficacy of dual treatment with orthokeratology lenses and 0.01% atropine eye drops: a focus on epithelial changes and tear film stability. BMC Ophthalmol. 2025;25:320. https:\/\/doi.org\/10.1186\/s12886-025-04151-3.","journal-title":"BMC Ophthalmol"},{"key":"71_CR51","doi-asserted-by":"publisher","first-page":"e0282286","DOI":"10.1371\/journal.pone.0282286","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang P, Jiang B, Meng Y, Qie S, Yan Z. The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: a meta-analysis. PLoS ONE. 2023;18:e0282286. https:\/\/doi.org\/10.1371\/journal.pone.0282286.","journal-title":"PLoS ONE"},{"key":"71_CR52","doi-asserted-by":"publisher","unstructured":"Matsumura S, Itokawa T, Kawakami M, Matsumoto T, Ishikawa H, Hori Y. Changes in choroidal thickness and blood flow in myopic children with 0.01% atropine or orthokeratology and atropine combination therapy. Acta Ophthalmol. 2025;103:974\u201383. https:\/\/doi.org\/10.1111\/aos.17537.","DOI":"10.1111\/aos.17537"},{"key":"71_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clae.2019.11.006","volume":"43","author":"P Gifford","year":"2020","unstructured":"Gifford P, Tran M, Priestley C, Maseedupally V, Kang P. Reducing treatment zone diameter in orthokeratology and its effect on peripheral ocular refraction. Cont Lens Anterior Eye. 2020;43:54\u20139. https:\/\/doi.org\/10.1016\/j.clae.2019.11.006.","journal-title":"Cont Lens Anterior Eye"},{"key":"71_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/ICL.0000000000001154","volume":"51","author":"HR Yum","year":"2025","unstructured":"Yum HR, Han SY, Park SH, Shin SY. Synergistic effect of dual-focus soft contact lenses and 0.05% atropine on myopia control in children with rapidly progressing myopia. Eye Contact Lens. 2025;51:92\u20137. https:\/\/doi.org\/10.1097\/ICL.0000000000001154.","journal-title":"Eye Contact Lens"},{"key":"71_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/OPX.0000000000001378","volume":"96","author":"J Huang","year":"2019","unstructured":"Huang J, Mutti DO, Jones-Jordan LA, Walline JJ. Bifocal & atropine in myopia study: baseline data and methods. Optom Vis Sci. 2019;96:335\u201344. https:\/\/doi.org\/10.1097\/OPX.0000000000001378.","journal-title":"Optom Vis Sci"},{"key":"71_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2024.100375","volume":"79","author":"DC Amaral","year":"2024","unstructured":"Amaral DC, Batista S, Dos Santos-Neto E, Manso JEF, Rodrigues MPM, Monteiro MLR, et al. Low-level red-light therapy for myopia control in children: A systematic review and meta-analysis. Clinics. 2024;79:100375. https:\/\/doi.org\/10.1016\/j.clinsp.2024.100375.","journal-title":"Clinics"},{"key":"71_CR57","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1136\/bjo-2023-323798","volume":"108","author":"E Zaabaar","year":"2024","unstructured":"Zaabaar E, Zhang XJ, Zhang Y, Bui CHT, Tang FY, Kam KW, et al. Light exposure therapy for myopia control: a systematic review and Bayesian network meta-analysis. Br J Ophthalmol. 2024;108:1053\u20139. https:\/\/doi.org\/10.1136\/bjo-2023-323798.","journal-title":"Br J Ophthalmol"},{"key":"71_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/tvst.13.8.31","volume":"13","author":"DJ Chang","year":"2024","unstructured":"Chang DJ, Jeong PLS, Saw J, Sevdalis SM, Najjar RP. Light therapy for myopia prevention and control: a systematic review on effectiveness, safety and implementation. Transl Vis Sci Technol. 2024;13:31. https:\/\/doi.org\/10.1167\/tvst.13.8.31.","journal-title":"Transl Vis Sci Technol"},{"key":"71_CR59","first-page":"128","volume":"65","author":"Y Hon","year":"2024","unstructured":"Hon Y, Chun RK-M, Cheung KK, Lam MK, Ho LM, Lam WC, et al. Bright light and combination of myopic defocus for myopia control: study design and demographic data. Invest Ophthalmol Vis Sci. 2024;65:128. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2795481.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR60","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ophtha.2024.05.023","volume":"131","author":"Y Xu","year":"2024","unstructured":"Xu Y, Cui L, Kong M, Li Q, Feng X, Feng K, et al. Repeated low-level red light therapy for myopia control in high myopia children and adolescents: a randomized clinical trial. Ophthalmology. 2024;131:1314\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2024.05.023.","journal-title":"Ophthalmology"},{"key":"71_CR61","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ophtha.2023.08.020","volume":"131","author":"W Zhou","year":"2024","unstructured":"Zhou W, Liao Y, Wang W, Sun Y, Li Q, Liu S, et al. Efficacy of different powers of low-level red light in children for myopia control. Ophthalmology. 2024;131:48\u201357. https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.020.","journal-title":"Ophthalmology"},{"key":"71_CR62","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ophtha.2022.10.002","volume":"130","author":"R Xiong","year":"2023","unstructured":"Xiong R, Zhu Z, Jiang Y, Wang W, Zhang J, Chen Y, et al. Longitudinal changes and predictive value of choroidal thickness for myopia control after repeated low-level red-light therapy. Ophthalmology. 2023;130:286\u201396. https:\/\/doi.org\/10.1016\/j.ophtha.2022.10.002.","journal-title":"Ophthalmology"},{"key":"71_CR63","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ophtha.2024.05.015","volume":"131","author":"R Xiong","year":"2024","unstructured":"Xiong R, Wang W, Tang X, He M, Hu Y, Zhang J, et al. Myopia control effect of repeated low-level red-light therapy combined with orthokeratology: a multicenter randomized controlled trial. Ophthalmology. 2024;131:1304\u201313. https:\/\/doi.org\/10.1016\/j.ophtha.2024.05.015.","journal-title":"Ophthalmology"},{"key":"71_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4133686","volume":"2024","author":"M Yu","year":"2024","unstructured":"Yu M, Tang X, Jiang J, Zhou F, Wang L, Xiang C, et al. Axial length shortening after combined repeated low-level red-light therapy in poor responders of orthokeratology in myopic children. J Ophthalmol. 2024;2024:4133686. https:\/\/doi.org\/10.1155\/2024\/4133686.","journal-title":"J Ophthalmol"},{"key":"71_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81363-5","volume":"15","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu S, Gao W, Wang L, Liu N, Zhang S, et al. Synergistic effect of defocus incorporated multiple segment glasses and repeated low level red light therapy against myopia progression. Sci Rep. 2025;15:3996. https:\/\/doi.org\/10.1038\/s41598-024-81363-5.","journal-title":"Sci Rep"},{"key":"71_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2025.104681","volume":"54","author":"CK Luo","year":"2025","unstructured":"Luo CK, Lai CY, Tan JH, Zhao W, Tan QQ. Efficacy of repeated low-level red-light therapy combined with defocus incorporated multiple segments spectacles for controlling childhood myopia. Photodiagnosis Photodyn Ther. 2025;54:104681. https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104681.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"71_CR67","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.62347\/DTLF6342","volume":"16","author":"G Wu","year":"2024","unstructured":"Wu G, Dai X, Tian J, Sun J. Efficacy of repeated low-level red-light therapy combined with optical lenses for myopia control in children and adolescents. Am J Transl Res. 2024;16:4903\u201311. https:\/\/doi.org\/10.62347\/DTLF6342.","journal-title":"Am J Transl Res"},{"key":"71_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1542620","volume":"12","author":"K Yang","year":"2025","unstructured":"Yang K, Wang Y, Li X, Liu S, Shi H, Qiao L. One-year changes in axial length and refraction in children using low-level red light and distant-image screen for myopia control: a randomized controlled trial. Front Med. 2025;12:1542620. https:\/\/doi.org\/10.3389\/fmed.2025.1542620.","journal-title":"Front Med"},{"key":"71_CR69","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaophthalmol.2023.1548","volume":"141","author":"H Liu","year":"2023","unstructured":"Liu H, Yang Y, Guo J, Peng J, Zhao P. Retinal damage after repeated low-level red-light laser exposure. JAMA Ophthalmol. 2023;141:693\u20135. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.1548.","journal-title":"JAMA Ophthalmol"},{"key":"71_CR70","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/opo.70009","volume":"45","author":"J Richards","year":"2025","unstructured":"Richards J, Hunter JJ, Gantes-Nu\u00f1ez J, Bradley A, Kollbaum P. Radiometric and safety assessment of a \u2018low-level red-light\u2019 myopia control device. Ophthalmic Physiol Opt. 2025;45:1905\u201311. https:\/\/doi.org\/10.1111\/opo.70009.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR71","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/opo.13272","volume":"44","author":"LA Ostrin","year":"2024","unstructured":"Ostrin LA, Schill AW. Red light instruments for myopia exceed safety limits. Ophthalmic Physiol Opt. 2024;44:241\u20138. https:\/\/doi.org\/10.1111\/opo.13272.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR72","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ctim.2008.04.007","volume":"16","author":"CK Liang","year":"2008","unstructured":"Liang CK, Ho TY, Li TC, Hsu WM, Li TM, Lee YC, et al. A combined therapy using stimulating auricular acupoints enhances lower-level atropine eyedrops when used for myopia control in school-aged children evaluated by a pilot randomized controlled clinical trial. Complement Ther Med. 2008;16:305\u201310. https:\/\/doi.org\/10.1016\/j.ctim.2008.04.007.","journal-title":"Complement Ther Med"},{"key":"71_CR73","doi-asserted-by":"publisher","first-page":"217","DOI":"10.36721\/PJPS.2026.39.1.REG.15269.1","volume":"39","author":"J Zhao","year":"2026","unstructured":"Zhao J, Zhong HL, Liu ZY, Xu Y. Clinical trial of press needle therapy with low-dose atropine for mild myopia in children. Pak J Pharm Sci. 2026;39:217\u201324. https:\/\/doi.org\/10.36721\/PJPS.2026.39.1.REG.15269.1.","journal-title":"Pak J Pharm Sci"},{"key":"71_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5585441","volume":"2021","author":"XH Kong","year":"2021","unstructured":"Kong XH, Zhao Y, Chen Z, Zeng L, Han R, Dong XQ, et al. A randomized controlled trial of the effect of 0.01% atropine eye drops combined with auricular acupoint stimulation on myopia progression. J Ophthalmol. 2021;2021:5585441. https:\/\/doi.org\/10.1155\/2021\/5585441.","journal-title":"J Ophthalmol"},{"key":"71_CR75","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ctim.2014.03.004","volume":"22","author":"HC Cheng","year":"2014","unstructured":"Cheng HC, Hsieh YT. The effect of low-concentration atropine combined with auricular acupoint stimulation in myopia control. Complement Ther Med. 2014;22:449\u201355. https:\/\/doi.org\/10.1016\/j.ctim.2014.03.004.","journal-title":"Complement Ther Med"},{"key":"71_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3928\/01913913-20250530-04","volume":"63","author":"Q Zhao","year":"2026","unstructured":"Zhao Q, Zhao Z, Zhao G, Xue L, Chen L, Zhou G, et al. Effect of defocus incorporated multiple segments (Fog Vision +0.50 D) combined with 0.01% atropine on the preclinical and early stages of myopia in children. J Pediatr Ophthalmol Strabismus. 2026;63:11\u201322. https:\/\/doi.org\/10.3928\/01913913-20250530-04.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"71_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84914-y","volume":"15","author":"Y Deng","year":"2025","unstructured":"Deng Y, Gao J, Mei Y, Ran WJ. Effects of racemic anisodamine in combination with orthokeratology and defocus incorporated multiple segment spectacle lenses for myopia control in adolescents. Sci Rep. 2025;15:8781. https:\/\/doi.org\/10.1038\/s41598-024-84914-y.","journal-title":"Sci Rep"},{"key":"71_CR78","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.1167\/iovs.14-14524","volume":"55","author":"A Benavente-P\u00e9rez","year":"2014","unstructured":"Benavente-P\u00e9rez A, Nour A, Troilo D. Axial eye growth and refractive error development can be modified by exposing the peripheral retina to relative myopic or hyperopic defocus. Invest Ophthalmol Vis Sci. 2014;55:6765\u201373. https:\/\/doi.org\/10.1167\/iovs.14-14524.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR79","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.visres.2009.07.011","volume":"49","author":"EL Smith","year":"2009","unstructured":"Smith EL, Hung LF, Huang J. Relative peripheral hyperopic defocus alters central refractive development in infant monkeys. Vis Res. 2009;49:2386\u201392. https:\/\/doi.org\/10.1016\/j.visres.2009.07.011.","journal-title":"Vis Res"},{"key":"71_CR80","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/icl.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens. 2020;46:129\u201335. https:\/\/doi.org\/10.1097\/icl.0000000000000677.","journal-title":"Eye Contact Lens"},{"key":"71_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115542","volume":"167","author":"K Thomson","year":"2023","unstructured":"Thomson K, Karouta C, Weber D, Hoffmann N, Morgan I, Kelly T, et al. The role of the serotonergic system in atropine\u2019s anti-myopic effects. Biomed Pharmacother. 2023;167:115542. https:\/\/doi.org\/10.1016\/j.biopha.2023.115542.","journal-title":"Biomed Pharmacother"},{"key":"71_CR82","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/opx.0000000000002083","volume":"100","author":"AD Salzano","year":"2023","unstructured":"Salzano AD, Khanal S, Cheung NL, Weise KK, Jenewein EC, Horn DM, et al. Repeated low-level red-light therapy: the next wave in myopia management?. Optom Vis Sci. 2023;100:812\u201322. https:\/\/doi.org\/10.1097\/opx.0000000000002083.","journal-title":"Optom Vis Sci"},{"key":"71_CR83","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/OPX.0b013e31826c1831","volume":"89","author":"Z Chen","year":"2012","unstructured":"Chen Z, Niu L, Xue F, Qu X, Zhou Z, Zhou X, et al. Impact of pupil diameter on axial growth in orthokeratology. Optom Vis Sci. 2012;89:1636\u201340. https:\/\/doi.org\/10.1097\/OPX.0b013e31826c1831.","journal-title":"Optom Vis Sci"},{"key":"71_CR84","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.002.","journal-title":"Ophthalmology"},{"key":"71_CR85","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/opo.12730","volume":"40","author":"SJ Vincent","year":"2020","unstructured":"Vincent SJ, Tan Q, Ng ALK, Cheng GPM, Woo VCP, Cho P. Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control. Ophthalmic Physiol Opt. 2020;40:728\u201337. https:\/\/doi.org\/10.1111\/opo.12730.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR86","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41433-021-01923-1","volume":"37","author":"J Tian","year":"2023","unstructured":"Tian J, Wei S, Li S, An W, Bai W, Liang X, et al. The effect of atropine 0.01% eyedrops on relative peripheral refraction in myopic children. Eye. 2023;37:356\u201361. https:\/\/doi.org\/10.1038\/s41433-021-01923-1.","journal-title":"Eye"},{"key":"71_CR87","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4919154","volume":"2020","author":"HY Sun","year":"2020","unstructured":"Sun HY, Lu WY, You JY, Kuo HY. Peripheral refraction in myopic children with and without atropine usage. J Ophthalmol. 2020;2020:4919154. https:\/\/doi.org\/10.1155\/2020\/4919154.","journal-title":"J Ophthalmol"},{"key":"71_CR88","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/opx.0000000000002249","volume":"102","author":"D Horn","year":"2025","unstructured":"Horn D, Salzano AD, Jenewein EC, Weise KK, Schaeffel F, Mathis U, et al. Topical review: potential mechanisms of atropine for myopia control. Optom Vis Sci. 2025;102:260\u201370. https:\/\/doi.org\/10.1097\/opx.0000000000002249.","journal-title":"Optom Vis Sci"},{"key":"71_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.62.10.36","volume":"62","author":"LA Jones-Jordan","year":"2021","unstructured":"Jones-Jordan LA, Sinnott LT, Chu RH, Cotter SA, Kleinstein RN, Manny RE, et al. Myopia progression as a function of sex, age and ethnicity. Invest Ophthalmol Vis Sci. 2021;62:36. https:\/\/doi.org\/10.1167\/iovs.62.10.36.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR90","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/opx.0000000000002176","volume":"101","author":"NA Brennan","year":"2024","unstructured":"Brennan NA, Shamp W, Maynes E, Cheng X, Bullimore MA. Influence of age and race on axial elongation in myopic children: a systematic review and meta-regression. Optom Vis Sci. 2024;101:497\u2013507. https:\/\/doi.org\/10.1097\/opx.0000000000002176.","journal-title":"Optom Vis Sci"},{"key":"71_CR91","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/bjophthalmol-2020-318256","volume":"106","author":"D Tricard","year":"2022","unstructured":"Tricard D, Marillet S, Ingrand P, Bullimore MA, Bourne RRA, Leveziel N. Progression of myopia in children and teenagers: a nationwide longitudinal study. Br J Ophthalmol. 2022;106:1104\u20139. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318256.","journal-title":"Br J Ophthalmol"},{"key":"71_CR92","doi-asserted-by":"publisher","first-page":"e0241759","DOI":"10.1371\/journal.pone.0241759","volume":"15","author":"PK Verkicharla","year":"2020","unstructured":"Verkicharla PK, Kammari P, Das AV. Myopia progression varies with age and severity of myopia. PLoS ONE. 2020;15:e0241759. https:\/\/doi.org\/10.1371\/journal.pone.0241759.","journal-title":"PLoS ONE"},{"key":"71_CR93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1167\/iovs.04-0565","volume":"46","author":"SM Saw","year":"2005","unstructured":"Saw SM, Tong L, Chua WH, Chia KS, Koh D, Tan DT, et al. Incidence and progression of myopia in Singaporean school children. Invest Ophthalmol Vis Sci. 2005;46:51\u20137. https:\/\/doi.org\/10.1167\/iovs.04-0565.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR94","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.optom.2019.06.002","volume":"13","author":"K Wong","year":"2020","unstructured":"Wong K, Dahlmann-Noor A. Myopia and its progression in children in London, UK: a retrospective evaluation. J Optom. 2020;13:146\u201354. https:\/\/doi.org\/10.1016\/j.optom.2019.06.002.","journal-title":"J Optom"},{"key":"71_CR95","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/opo.13259","volume":"44","author":"M Moore","year":"2024","unstructured":"Moore M, Lingham G, Flitcroft DI, Loughman J. Myopia progression patterns among paediatric patients in a clinical setting. Ophthalmic Physiol Opt. 2024;44:258\u201369. https:\/\/doi.org\/10.1111\/opo.13259.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR96","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123:697\u2013708. https:\/\/doi.org\/10.1016\/j.ophtha.2015.11.010.","journal-title":"Ophthalmology"},{"key":"71_CR97","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1% and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"key":"71_CR98","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062.","journal-title":"Ophthalmology"},{"key":"71_CR99","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.11-8453","volume":"53","author":"T Hiraoka","year":"2012","unstructured":"Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913\u20139. https:\/\/doi.org\/10.1167\/iovs.11-8453.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"71_CR100","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/opo.13120","volume":"43","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA, Flitcroft DI. The future of clinical trials of myopia control. Ophthalmic Physiol Opt. 2023;43:525\u201333. https:\/\/doi.org\/10.1111\/opo.13120.","journal-title":"Ophthalmic Physiol Opt"},{"key":"71_CR101","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ophtha.2022.06.024","volume":"129","author":"X He","year":"2022","unstructured":"He X, Sankaridurg P, Wang J, Chen J, Naduvilath T, He M, et al. Time outdoors in reducing myopia: a school-based cluster randomized trial with objective monitoring of outdoor time and light intensity. Ophthalmology. 2022;129:1245\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2022.06.024.","journal-title":"Ophthalmology"},{"key":"71_CR102","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ophtha.2017.12.011","volume":"125","author":"PC Wu","year":"2018","unstructured":"Wu PC, Chen CT, Lin KK, Sun CC, Kuo CN, Huang HM, et al. Myopia prevention and outdoor light intensity in a school-based cluster randomized trial. Ophthalmology. 2018;125:1239\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.011.","journal-title":"Ophthalmology"},{"key":"71_CR103","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.4103\/IJO.IJO_744_23","volume":"71","author":"PK Verkicharla","year":"2023","unstructured":"Verkicharla PK, Thakur S, Kekunnaya R, Dhakal R, Manoharan MK, Gupta SK, et al. The \u201cIMPACT\u201d myopia management guidelines. Indian J Ophthalmol. 2023;71:2882\u20134. https:\/\/doi.org\/10.4103\/IJO.IJO_744_23.","journal-title":"Indian J Ophthalmol"},{"key":"71_CR104","doi-asserted-by":"publisher","unstructured":"Sankaridurg P, Chia A, Kang P. Should combination treatments be the standard of care to maximise efficacy for myopia treatment? Ophthalmic Physiol Opt. 2025;45:918\u201322. https:\/\/doi.org\/10.1111\/opo.13474.","DOI":"10.1111\/opo.13474"},{"key":"71_CR105","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/opx.0000000000002119","volume":"101","author":"MA Bullimore","year":"2024","unstructured":"Bullimore MA, Jong M, Brennan NA. Myopia control: seeing beyond efficacy. Optom Vis Sci. 2024;101:134\u201342. https:\/\/doi.org\/10.1097\/opx.0000000000002119.","journal-title":"Optom Vis Sci"}],"container-title":["Ophthalmic and Physiological Optics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44402-026-00071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44402-026-00071-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44402-026-00071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:36:00Z","timestamp":1783694160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44402-026-00071-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s44402-026-00071-x","relation":{},"ISSN":["0275-5408","1475-1313"],"issn-type":[{"value":"0275-5408","type":"print"},{"value":"1475-1313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST and TH have no conflict of interest. MAB is a consultant for Alcon Research, Bruno Vision Care, CooperVision, Dopavision, EssilorLuxottica, Euclid Vision, Eyenovia, Genentech, Johnson & Johnson, Kubota Vision, Santen Pharmaceutical, SightGlass Vision, Sydnexis, Laboratoires Th\u00e9a, Xingqi Pharmaceutical, Vyluma; ZC is a consultant for SightGlass Vision, EssilorLuxottica, Euclid System, VisionX, Zeiss Vision China; PKV has received funding from SEED, Nthalmic, EssilorLuxottica, and filed patents for Peripheral-Ancillary Refractive Component (PARC) and Myopia predictive technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}